Sugi Predict

Sugi Predict / Compounds / SCHEMBL19981705

SCHEMBL19981705

SCHEMBL19981705

CC(C)CNNC(=O)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ GAA P10253 2/20 0.38
▸ MMP1 P03956 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ HDAC3 O15379 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ ADH1B P00325 1/20 0.33
▸ ADH1C P00326 1/20 0.33
▸ ADH1A P07327 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KISS1R Q969F8 2/20 0.31
▸ EPHX1 P07099 2/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8844118 0.77 — —
SCHEMBL22364028 0.77 — —
SCHEMBL5723527 0.77 — —
SCHEMBL24253280 0.75 — —
SCHEMBL5300435 0.75 — —
SCHEMBL18466266 0.75 — —
SCHEMBL605889 0.74 GAA (0.48) GAAALDH1A1KDM4EHTTKMT2A
SCHEMBL3354440 0.74 CYP2D6 (0.59) CYP2D6CYP2C19GAAMMP1MMP8
SCHEMBL22824825 0.73 CYP2D6 (0.41) CYP2D6CYP2C19GAAMMP1MMP8
SCHEMBL6638050 0.73 CYP2D6 (0.41) CYP2D6CYP2C19GAAMMP1MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2023-08-22 — — US disclosed
US-11332535-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IMMUNOGEN, INC. (US) 2022-05-17 — — US disclosed
US-11135308-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2021-10-05 — — US disclosed
US-20210147560-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IMMUNOGEN, INC. 2021-05-20 — — US disclosed
US-10988531-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2021-04-27 — — US disclosed
US-10919969-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IMMUNOGEN, INC. (US) 2021-02-16 — — US disclosed
US-10875925-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IMMUNOGEN, INC. (US) 2020-12-29 — — US disclosed
US-10792372-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2020-10-06 — — US disclosed
US-20200239580-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IMMUNOGEN, INC. 2020-07-30 — — US disclosed
US-20200197531-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN, INC. 2020-06-25 — — US disclosed
US-10442865-B2 Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof IMMUNOGEN, INC. (US) 2019-10-15 — — US disclosed
US-20180079819-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IMMUNOGEN, INC. 2018-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200197531-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VIP, AREG, MIF CYP2D6 4317/4885CYP2C19 3914/4885GAA 1422/4885
US-20180079819-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885
US-20210147560-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents PCNA, EPCAM, MKI67 CYP2D6 1398/4885CYP2C19 3692/4885GAA 255/4885
US-10442865-B2 Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof IL23R, CD22, IL2RA CYP2D6 3939/4885CYP2C19 3855/4885GAA 2345/4885
US-11135308-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF CYP2D6 4317/4885CYP2C19 3914/4885GAA 1422/4885
US-10792372-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF CYP2D6 4317/4885CYP2C19 3914/4885GAA 1422/4885
US-10875925-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885
US-10988531-B2 Conjugates comprising cell-binding agents and cytotoxic agents PCNA, EPCAM, MKI67 CYP2D6 1398/4885CYP2C19 3692/4885GAA 255/4885
US-10919969-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885
US-20200239580-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885
US-11332535-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IL23R, CD22, IL2RA CYP2D6 2761/4885CYP2C19 2796/4885GAA 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.